Bank of America Corp DE Purchases 101,469 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Bank of America Corp DE grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 1,291,053 shares of the biopharmaceutical company's stock after acquiring an additional 101,469 shares during the period. Bank of America Corp DE owned about 1.25% of Regeneron Pharmaceuticals worth $805,023,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in REGN. BlackRock Inc. bought a new position in Regeneron Pharmaceuticals in the second quarter worth $5,682,636,000. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $1,012,296,000. Nuveen LLC grew its position in shares of Regeneron Pharmaceuticals by 71.1% in the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company's stock worth $1,551,858,000 after buying an additional 835,240 shares during the period. Legal & General Group Plc bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $473,872,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $472,950,000. Institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

REGN has been the topic of several research reports. Leerink Partners boosted their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a "market perform" rating in a research note on Monday, August 17th. Benchmark raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 target price for the company in a research note on Tuesday, July 7th. HSBC lifted their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a "buy" rating in a report on Thursday, September 10th. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a "hold" rating in a research report on Wednesday, July 29th. Finally, Canaccord Genuity Group cut their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a "buy" rating on the stock in a research note on Tuesday, May 19th. Fourteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $802.18.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: One analysis argues that REGN could be approximately 5% undervalued even after the trial-related lawsuit news. The stock remains up 29.12% over the past 90 days and has delivered a 39.33% one-year total shareholder return, suggesting that investors continue to see value in Regeneron’s commercial products and development pipeline. Regeneron Pharmaceuticals Could Be 5% Undervalued Following Trial Lawsuit News
• Positive Sentiment: Regeneron’s presence in ophthalmology and immunology, along with strategic collaborations and pipeline expansion, remains a key part of the investment case. Its latest reported quarter also featured revenue growth and a significant earnings beat, providing fundamental support despite near-term headline risk. Novo Nordisk vs. Regeneron Pharmaceuticals
• Neutral Sentiment: A Morgan Stanley healthcare conference presentation provided investors with an opportunity to assess Regeneron’s strategy and pipeline, but the available transcript headline did not identify a specific new catalyst or material change to forecasts. Regeneron Morgan Stanley Healthcare Conference Transcript
• Neutral Sentiment: Industry research projects continued growth in bispecific antibody treatments through 2036. This could support the long-term opportunity for companies with relevant programs, although the report does not announce a new Regeneron product or clinical result. Bispecifics Market Forecast
• Negative Sentiment: Several law firms have announced or promoted federal securities class actions alleging that Regeneron understated risks and used overly optimistic assumptions regarding the Phase III Fianlimab-Libtayo trial, which is intended to treat melanoma. The lawsuits introduce potential legal costs, reputational risk and additional uncertainty around a key pipeline asset, helping explain the recent weakness in REGN. The allegations have not been proven in court. Fianlimab-Libtayo Trial Misstatement Lawsuits REGN Securities Class Action Lead Plaintiff Deadline

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $774.11 on Wednesday. The stock has a market capitalization of $79.70 billion, a PE ratio of 19.13, a price-to-earnings-growth ratio of 1.56 and a beta of 0.20. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $859.34. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The stock's 50 day simple moving average is $759.76 and its 200 day simple moving average is $720.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company's quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the company earned $12.81 EPS. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is currently 9.29%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur Ryan sold 200 shares of the firm's stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company's stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the sale, the director owned 603 shares of the company's stock, valued at approximately $512,550. This represents a 39.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,146 shares of company stock worth $3,432,488 in the last three months. 6.97% of the stock is owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron's marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.